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Abstract
Background: The unified protocol for the transdiagnostic treatment of emotional disorders is a promising
treatment approach that could be applicable to a broad range of mental disorders, including depressive, anxiety,
trauma-related, and obsessive-compulsive disorders. However, no randomized controlled trial has been conducted
to verify the efficacy of the unified protocol on the heterogeneous clinical population with depressive and anxiety
disorders.
Methods/design: The trial was designed as a single-center, assessor-blinded, randomized, 20-week, parallel-group
superiority study in order to compare the efficacy of the combination of unified protocol and treatment-as-usual
versus waiting-list with treatment-as-usual for patients with depressive and/or anxiety disorders. The primary
outcome was depression at 21 weeks, assessed by the 17-item version of the GRID-Hamilton Rating Scale for
Depression. Estimated minimum sample size was 27 participants in each group. We will also examine the treatment
mechanisms, treatment processes, and neuropsychological correlates.
Discussion: The results of this study will clarify the efficacy of the unified protocol for depressive and anxiety
disorders, and the treatment mechanism, process, and neurological correlates for the effectiveness of the unified
protocol. If its efficacy can be confirmed, the unified protocol may be of high clinical value for Japan, a country in
which cognitive behavioral treatment has not yet been widely adopted.
Trial Registration: ClinicalTrials.gov NCT02003261 (registered on December 2, 2013)
Keywords: Anxiety disorder, Depressive disorder, Emotion, Transdiagnostic, Unified protocol, Randomized
controlled trial
Background
Transdiagnostic treatment for emotional disorders
Emotion is one of the biggest sources of human distress.
Symptoms of emotional difficulties, in particular depres-
sion and anxiety, are among the most common symp-
toms observed in psychiatric and clinical-psychological
settings. Lifetime prevalence of depressive and anxiety
disorders is estimated at 6.3 and 6.7 % in Japan [1], and
16.6 and 28.8 % each in the U.S. [2]. Depressive and anx-
iety disorders were respectively ranked as the second-
and ninth-largest causes of global years lived with
disability in 2013 [3], and depressive disorders in par-
ticular are predicted to become the first cause of disease
burden by 2030 [4]. The economic burden of depressive
disorder has been enormous ($11–18 billion in Japan
and $173–211 billion in the U.S. in 2010) [5–7]. Simi-
larly, the economic burden of anxiety disorders was re-
ported as $20.5 billion in Japan and $42.3 billion in the
U.S. in 1990 [8, 9]; and it should be noted that this figure
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for anxiety disorders in the U.S. could be greatly underes-
timated, because it did not consider long-term opportun-
ity cost or the cost associated with comorbidity, which
could bring total costs to the U.S. economy as a result of
anxiety disorder to an estimated $100 billion [10].
Depressive and anxiety disorders, which are commonly
comorbid, are both conceptualized as disorders of emo-
tion [11]. Accumulated findings show shared psycho-
pathology, etiology, neurobiological characteristics, and
similar cognitive-affective, interpersonal, and behavioral-
maintenance factors commonly observed among depres-
sion, anxiety, and trauma-related, obsessive-compulsive,
and other emotion-related disorders [11–15]. These find-
ings leads to the idea of transdiagnostic conceptualization
of these disorders [16]; the term often used is “emo-
tional disorders” [15]. This broad category includes,
at minimum, the Diagnostic and Statistical Manual
of Mental Disorders 5th edition (DSM-5) categories
of depressive disorders, anxiety disorders, trauma-
related disorders, and obsessive-compulsive disorders
[15, 17].
Cognitive behavioral therapy (CBT) has been shown
to be an efficacious treatment for emotional disorders
[18, 19], and is recommended by treatment guidelines
as a high-intensity treatments for depressive and anxiety
disorders [20–28]. Most CBT protocols have been devel-
oped to treat one specific disorder. Recently, however, the
accumulated evidence of shared psychopathology has
influenced not only the conceptualization of emotional
disorders, but also their treatment. Transdiagnostic psy-
chological treatment has been developed to treat depres-
sion, anxiety, and trauma-related, obsessive-compulsive,
and other emotion-related disorders by targeting their
shared psychopathology [11, 29, 30]. The transdiagnos-
tic approach has several potential strengths over the
disorder-specific treatment: applicability to diverse dis-
orders with comorbidity, simplification of treatment
models for diverse emotional disorders, and ease of
learning for novice therapists [30, 31].
Though the transdiagnostic approach for emotional
disorders has been proposed only relatively recently, un-
controlled/nonrandomized and randomized controlled
trials (RCTs) have already been mounted to investigate
its efficacy and feasibility. Transdiagnostic psychological
treatments vary in format (individual, group, internet),
theoretical orientation (transdiagnostic cognitive behavior
therapy, transdiagnostic mindfulness- and acceptance-
based treatments), strictness or flexibility of the applica-
tion of the protocol to individual patients, and range of
disorders covered (anxiety disorders only, both anxiety
and depressive disorders). The latest meta-analysis has
identified 47 clinical trials (31 RCTs) on the transdiagnos-
tic approach, with a total of 3705 participants. That study
reported the cumulative effect sizes of transdiagnostic
CBT on self-report measures among patients with diag-
nosis of depressive and/or anxiety disorders, in com-
parison to control groups (waiting-list, supportive
counseling, psychoeducation, treatment-as-usual, etc.):
medium for anxiety (n = 24, g = .65, 95 % CI .51–.79),
large for depression (n = 22, g = .80, 95 % CI .62–.98),
and medium for quality of life (n = 13, g = .46, 95 % CI
.34–.57) [32, 33].
Despite the promise of transdiagnostic treatment,
there are several limitations to it in its current state.
First, the evidence of its efficacy is still inconclusive, be-
cause most existing trials have had a high risk of bias
and because there is significant heterogeneity between
the trials [32, 33]. Newby et al. reported that only seven
out of 31 RCTs were rated low risk for bias in all of five
criteria (namely, random sequence, concealment, blind-
ing of assessors, incomplete outcome data, selective
reporting); and clinical trials for transdiagnostic treat-
ment on anxiety and depression in comparison to con-
trol group(s) have been shown to have moderate
heterogeneity (I2 = 51–83 %) [32, 33]. More importantly,
the latest meta-analysis did not examine the results for
clinician-rated measures, because only 13 out of 31
RCTs reported an independent assessor rating for a
structured clinical interview, and the interviews used
varied from trial to trial. Second, no RCT for transdiag-
nostic CBT has been conducted in non-Western coun-
tries, which means that transdiagnostic treatment
cannot yet be regarded as a transcultural treatment [12].
Third, only eight out of 31 RCTs have included both de-
pressive and anxiety disorders, which are the putative
populations for transdiagnostic treatment, which means
that, many trials included a sub-category of anxiety dis-
orders only. It is necessary to include transdiagnostic
clinical populations in clinical trials to examine the
external validity (i.e., generalizability) of the findings.
Fourth, few studies have examined the putative treat-
ment mechanism that rationalizes the treatment as
transdiagnostic (e.g., neuroticism, emotion regulation)
[12, 34]. Fifth, no study has examined the neuropsycho-
logical underpinnings of transdiagnostic treatment.
Unified protocol for the transdiagnostic treatment of
emotional disorders (UP)
The UP is one of the most empirically well-supported
transdiagnostic psychological treatments [33, 35]. It
was developed based on the recognition of diagnostic
overlap across emotional disorders (i.e., comorbidity),
non-specificity of treatment response to comorbid symp-
toms by diagnosis-specific treatments, latent structure of
emotional disorders (e.g., negative affectivity), etiology,
and commonality of findings of affective neuroscience on
emotional disorders (e.g., reductions in connectivity be-
tween the amygdala and ventromedial prefrontal cortex)
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[11, 13]. Evidence relating to individual UP has been
reported in various forms: theoretical paper [11, 13], case
report [36], pilot clinical trial [37], and RCT with waiting-
list [38]. Moreover, the feasibility of UP has been extended
to individual and group formats for depressive and anxiety
disorders [39], individual format for bipolar disorder [40],
borderline personality disorder [41], and emotional disor-
ders in adolescents [42].
The existing evidence, however, should be regarded as
preliminary at best [12]. Findings by RCT to date are
limited to one trial each for individual- and group-
format UP, with small sample sizes [38, 39]. Further,
there is clear lack of evidence regarding UP efficacy for
depressive disorders and for Asian populations. Previous
pilot studies for individual UP have examined only three
patients with the principal diagnosis of major depressive
disorder [36–38], and there is no RCT of UP efficacy for
depressive disorders. Comparative clinical trials have
been limited to one in the U.S. and one in Brazil [39].
Thus, we aimed to examine the efficacy of UP for
Japanese patients with either or both depressive and
anxiety disorders. Though such a broad category of par-
ticipants constitutes a heterogeneous clinical population
in terms of the standard diagnostic criteria (i.e., DSM-5
or International Classification of Diseases 10th revision;
ICD-10) and leads to some methodological challenges
unique to transdiagnostic treatment [43], we neverthe-
less selected this population because the unified protocol
was originally developed to treat heterogeneous clinical
populations transdiagnostically.
Primary hypothesis and objectives
We hypothesize that the addition of the unified protocol
to patients’ usual treatment by psychiatrists would be
more efficacious in comparison to waiting-list for UP
with usual treatment for the reduction of emotional
symptoms among patients with depressive and anxiety
disorders in a Japanese outpatient clinical setting.
Treatment mechanism and process for enhancing the
effectiveness of implementation of unified protocol
Though this clinical trial is mounted primarily to test
the efficacy of the unified protocol on the primary out-
come (i.e., emotional symptoms), it is also important to
examine the treatment mechanism, process, and neuro-
logical correlates [12, 32]. Furthermore, because the UP
was developed based on the findings on the shared
underlying process of psychopathology across a wide
range of emotional disorders (depressive, anxiety, trauma-
related, and obsessive-compulsive disorders), it is import-
ant to examine how this shared process actually relates to
the outcome of the treatment. These examinations are ex-
pected to not only allow theoretical refinement of UP, but
also sharpen its clinical implementation. We focus on four
different variables to examine the treatment mechanism;
neuroticism, emotion regulation, emotion exposure, and
anxiety sensitivity. These variables are considered to be
transdiagnostic mediators/moderators of the treatment.
Neuroticism here refers to the shared aspects of tempera-
ment commonly observed between depressive and anxiety
disorders [44, 45]. Deficits of emotion regulation are also
a putative transdiagnostic treatment mechanism of CBT
[19, 34, 46]: through UP, patients will learn to engage
adaptive emotion regulation and disengage maladaptive
emotion regulation. The core module of the unified
protocol is emotion exposure [35]; theoretically, the
other modules will be expected to function to maximize
the therapeutic effect of emotion exposure [11], and
hence the patient’s ability to expose themselves to their
own emotion should be one of the key focuses in terms
of treatment mechanisms [47, 48]. Finally, anxiety sen-
sitivity is regarded as the transdiagnostic process affect-
ing the (non) maintenance of emotional disorders [49].
The effects of psychotherapy depend on its process:
who delivers the protocol, how it is delivered, the degree
to which the patient understands the concept or prac-
tices the skill, etc. [47, 50, 51]. Past studies suggest that
strict adherence to CBT protocols does not linearly pre-
dict the treatment outcome [52, 53]. Hence, it is not
enough to monitor adherence to the treatment protocol;
one must also assess various aspects of the implementa-
tion or processes of the psychotherapy. In this clinical
trial, we will collect some of the most important process
measures regarding the implementation of the unified
protocol. These include treatment expectancy [54, 55],
therapeutic relationship [56–58], homework compliance
[47, 59–61], and patient comprehension of treatment ra-
tionale. Examination of the relationships between these
process measures and treatment outcome is expected to
inform and help optimize the implementation of UP for
patients with emotional disorders.
Neurological correlates regarding the unified protocol
To the best of our knowledge, no study has yet examined
neurological change after the intervention of transdiagnos-
tic treatment; nevertheless, the existence of transdiagnostic
neurological commonalities across emotional disorders has
been suggested. Some researchers have developed the
transdiagnostic neural model [62, 63] to reflect this. Recent
studies have been focused more on the similarity of neural
systems between depression and anxiety disorders, in
addition to the differences [64]; this focus is consistent with
the view taken by the Research Domain Criteria project of
the U.S. National Institute of Mental Health [65]. In fact,
neurobiological studies have shown some similarity in
changes from before to after CBT across emotional disor-
ders [66]. Considering that UP is a transdiagnostic treat-
ment partly based on findings from the field of affective
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neuroscience [13], transdiagnostic change at the neuro-
logical level is indeed expected across emotional disorders.
Moreover, recent investigation of the domain of neuro-
psychological perspective has predicted treatment efficacy
using neurological measures; for example, Ball et al. [67]
showed that the random forest model using pre-treatment
neuroimaging data predicted treatment response of gener-
alized anxiety disorder and panic disorder patients with
good test characteristics. Hence, we will correct these
neuropsychological data as an ancillary study.
Methods/design
Trial design, randomization, and ethical aspects
This study is a single-center, assessor-blinded, random-
ized, parallel-group superiority design with a target sam-
ple of 54 patients with depressive or anxiety disorders.
Participant flow is depicted in Fig. 1. We will employ
central randomization using Allocation and Registration
Control System (ARCS) computer software, set up and
managed independently of the study by the Project
Management Office at the Keio Center for Clinical
Research. A random sequence will be generated using
minimization, with a ratio of 1:1 to balance stratified
factors (depressive vs. anxiety disorder). Allocation will
be implemented by the primary investigator or research
coordinator via internet using a laptop in front of the
eligible participant. This protocol has been reviewed
and approved by the institutional review board of the
(Japanese) National Center of Neurology and Psychiatry
(accepted on October 18, 2013; A2013-092). All partici-
pants will give written informed consent to participation
in the study. This trial is registered within ClinicalTrials.
gov, number NCT02003261.
Study setting
This single-site study has been conducted at the
National Center of Neurology and Psychiatry (NCNP)
Hospital in Tokyo; this is the national hospital specializ-
ing in the research and treatment of psychiatric, neuro-
logical, muscular, and developmental diseases in Japan.
The hospital provides mainly secondary or tertiary in-
patient and outpatient psychiatric treatments to socio-
economically diverse Japanese populations. Most new
patients are referred to the NCNP Hospital because of
non-response on their part to their usual care in their
local clinic or hospital. Participants eligible for our pilot
study had a long history from the first onset of the
disorder (Mean months = 93.64, SD = 80.7) [68]. Treat-
ment for depressive and anxiety disorders, usually pro-
vided in the NCNP Hospital outpatient department, had
largely consisted of pharmacotherapy, supportive ther-
apy, or active monitoring. Totals of 1017 and 2138 CBT
sessions were respectively conducted in fiscal 2013 and
2014 at the hospital. In the Japanese medical setting, all
patients basically continue their usual treatment with
their treating psychiatrists when receiving any psycho-
social treatments at the same medical institute. In the
other words, the psychologist is not able to conduct any
intervention with patients without the permission or dir-
ection of the treating psychiatrist. Along with the need
for medical monitoring and clinical management, this is
why all participants in both intervention and control
Fig. 1 CONSORT diagram for this clinical trial
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groups need to continue treatment-as-usual (TAU) even
if they are not pharmacologically prescribed. Japan’s uni-
versal health insurance system allows every Japanese
resident to have access to any medical services at any
medical institution nationwide without a gatekeeper and
helps them pay incurred medical costs.
Eligibility criteria
Participants need to fulfill all of the following inclusion
criteria and to not meet any of the following exclusion
criteria. We used DSM-IV criteria because the Japanese
version of the DSM-5 had not yet been finalized and
there was no structured method for diagnosing DSM-5
criteria (e.g., SCID-5) at the start of this trial.
Inclusion criteria
1. DSM-IV diagnosis of Major Depressive Disorder,
Dysthymia, Depressive Disorder Not Otherwise
Specified, Panic Disorder With Agoraphobia, Panic
Disorder Without Agoraphobia, Agoraphobia
Without History of Panic Disorder, Social Phobia
(Social Anxiety Disorder), Obsessive-Compulsive
Disorder, Posttraumatic Stress Disorder, Generalized
Anxiety Disorder, Anxiety Disorder Not Otherwise
Specified; as assessed by Structural Clinical Interview
for DSM-IV-TR Axis I Disorders (SCID-IV-TR).
2. Depressive and anxiety symptoms are mild or
severer (i.e., not absent) (GRID–Hamilton Rating
Scale for Depression: GRID-HAMD > = 8).
3. Aged 20–65 years.
4. Gives full informed consent to participate in the
study.
Exclusion criteria
1. No alcohol or substance use disorder in 6 months
prior to the baseline assessed by SCID-IV-TR.
2. No current manic episode or current schizophrenia
or other psychotic disorder at baseline assessed by
SCID-IV-TR.
3. No serious suicidal ideation at baseline (GRID-HAMD
Item 3 symptom intensity is less than moderate).
4. No life-threatening, severe, or unstable physical
disorders or major cognitive deficits at baseline.
5. No evidence of inability to participate in half or
more of the intervention phase.
6. No structured psychotherapy at baseline.
7. Other relevant reason as determined by the
investigators.
Intervention
We compare the UP with TAU intervention group with
the waiting-list with TAU control group.
UP
UP is an transdiagnostic cognitive behavior therapy for
emotional disorders [35]. Complete implementation usu-
ally takes 12–18 weekly sessions of 50–60 min each.
Patient use the treatment workbook throughout the
treatment [69], and practice newly learned cognitive-
behavioral skills in between sessions. In this study,
patients will receive approximately 16 face-to-face, indi-
vidual sessions (range: 9–20) within 20 weeks. The therap-
ist can shorten or lengthen needed sessions or intervals
(weekly or biweekly) in accordance with the patient’s level
of understanding or acquisition of the skills. Up to five
additional sessions during the follow-up period for the
intervention group will be allowed if the therapist and
patient deem it necessary and if the patient has not
completed all modules.
The unified protocol consists of one introductory
session and eight modules for learning transdiagnostic
cognitive behavioral skills: motivation enhancement, psy-
choeducation of emotion, emotion awareness training,
cognitive reappraisal, emotion avoidance and emotion-
driven behavior, tolerance training for physical sensations,
emotion exposure, and relapse prevention (Table 1).
Details of this intervention are described in the therapist’s
guide to UP [35]. To be eligible for this clinical trial, a
therapist needs to be qualified as a clinical psychologist by
the Foundation of the Japanese Certification Board for
Clinical Psychologists or possess a Japanese physician’s
license, to have received adequate training using the thera-
pist’s guide for UP and the CBT treatment manual pub-
lished by the Japanese Ministry of Health, Labour and
Welfare (at least 10 h of workshops), and to sit in on or
listen to the full treatment course of at least two UP cases.
At the beginning of this trial, four therapists (two females;
clinical practice after certification of 4–6 years; experience
of UP cases, 3–8 cases) were registered as staff therapists.
Treatment adherence will be monitored by weekly
group supervision and assessed using the Treatment
Adherence Scale for UP. Two clinical psychologists
(MH, MI), who translated the UP workbook and therap-
ist guide, will supervise the study therapist. MH has clin-
ical experience of more than 20 years. (MI will also
serve as a staff therapist.) The Treatment Adherence
Scale was developed by the developer of the unified
protocol, and consists of 74 adherence items (12 for ini-
tial session, four for motivation enhancement, nine for
psychoeducation, eight for emotion awareness training,
eight for cognitive reappraisal, 11 for emotion avoidance
and emotion-driven behavior, seven for tolerance of
physical sensations, eight for emotion exposure, seven
for relapse prevention). Items are rated according to
whether the intervention has been implemented or not
(Yes or No). To assess treatment adherence, we ran-
domly select one-fourth of each participant’s sessions.
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The simple random sampling procedure was conducted
using the True Randomization process (www.random.org)
before the beginning of this clinical trial. The evaluation
was conducted by a therapist who did not serve as a staff
therapist for this study.
TAU
Though treatments for depressive and anxiety disorders
in Japanese medical settings have not been systematically
investigated, the majority seem to involve pharmacother-
apy, unsystematic supportive therapy, or clinical moni-
toring by psychiatrists. The Japanese Society of Mood
Disorders has published treatment guidelines for Major
Depressive Disorders (MDDs) that recommend pharma-
cotherapy for moderate or severe MDD patients and
pharmacotherapy and psychotherapy for mild MDD
patients [70]. However, there are no such treatment
guidelines for anxiety disorders specific to Japanese clini-
cians. One study showed that Japanese psychiatrists tend
to choose pharmacotherapy for the first and second in-
stance of treatment of MDD [71], and the results of our
pilot study showed that almost all participants had re-
ceived pharmacotherapy [68]. Based on the knowledge,
we expected TAU for depressive and anxiety symptoms
to be mostly pharmacotherapy. For this clinical trial, we
defined TAU as any pharmacological or (non-systematic)
psychological intervention except for systematic psycho-
therapy (e.g., any other type of cognitive behavioral ther-
apy) and electroconvulsive therapy. We considered that the
clinical success of participant’s treatment should be priori-
tized over our research purpose. Hence, we will not restrict
any usual treatment by treating psychiatrists, including
change of dose or type of drug. If treating psychiatrists start
other systematic psychotherapy (e.g., another type of cogni-
tive behavioral therapy) or electroconvulsive therapy, the
patient will be excluded from the intervention in this study.
Content of TAU will be documented in case report form.
Follow-up phase
We set the assessment period at 43 weeks in order to
exploratorily examine the trajectory after treatment for
the intervention group. Participants assigned to the con-
trol group will receive the unified protocol in addition to
TAU during the follow-up period (21–43 weeks). Data
including the 43-week assessment will be used to explor-
atorily examine the persistence of the effect for the
intervention group as well as the immediate treatment
effect for the control group. There will be no treatment
restrictions on the intervention group in the follow-up
period.
Discontinuation
Any participant in the intervention group who meets
any of the discontinuation criteria will have their inter-
vention (UP) stopped. Where possible, subsequent as-
sessment will be conducted.
1. Participant request for discontinuation or participant
withdrawal of consent.
2. Inability to contact the participant for a month.
3. Difficulty continuing the intervention because of a
severe adverse event.
4. Difficulty continuing the intervention because of the
exacerbation of comorbid symptoms.
5. Participant proves after assignment not to fulfill the
eligibility criteria.
6. The whole clinical trial is stopped.
7. Any other reason that the primary investigator,
therapist, and supervisor agree to warrants
discontinuation.
Measures
We will assess several measures of outcome, treatment
mechanism, process, and neurological correlates. Most
assessments will be conducted at baseline (0 weeks),
10 weeks (mid assessment), 21 weeks (post assessment),
and 43 weeks (follow-up assessment). Table 2 shows the
list and schedule of assessments.
Primary outcome
The primary outcome is change of depressive symptoms
over the intervention period as assessed by the 17-item
version of the semi-structured interview included in the
GRID–Hamilton Depression Rating Scale (GRID-HAMD)
[72–74]. GRID-HAMD employs a “grid” scoring system
using the dimensions of symptom intensity and symptom
frequency; higher scores indicate severer depressive symp-
toms (range: 0–52). This interview instrument has been
reported to have excellent interrater reliability among
Japanese clinicians (intraclass correlation coefficient; ICC
= 0.95–0.99) [73], a finding borne out by our pilot study
(ICC = .974, 95%CI = .966–.980) [68]. Internal consistency
Table 1 Outline of Unified Protocol
Numbers of sessions needed Module
1 Introduction to treatment
1–2 Motivation enhancement
1–2 Psychoeducation of emotional experiences
1–2 Emotion awareness traininga
1–2 Cognitive appraisal and reappraisala
1–2 Emotion avoidance and emotion-driven
behaviorsa
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was reported to be 0.78 [74]. The interview instrument’s
concurrent validity was demonstrated by high correlation
between item and total score per the structured interview
guide for HAMD [74]. We decided to use GRID-HAMD
to assess “emotional symptoms” because it assesses not
only depressive symptoms (depressed mood, guilt, suicide,
insomnia early, insomnia middle, insomnia late, work and
activities, psychomotor retardation, psychomotor agita-
tion, loss of appetite, loss of sexual interest, loss of weight,
and loss of insight) but also anxiety symptoms (psychic
and somatic anxiety, general somatic symptoms, and
hypochondriasis). Moreover, the GRID-HAMD is an
appropriate choice for our study because it is one of the
few depression rating measures that has been validated in
Japanese and utilized in many clinical trials in Japan
[75, 76], making implementation of assessment more
straightforward. In our pilot study, we used GRID-HAMD
and the Structured Interviews Guide for Hamilton Rating
Scale for Anxiety (SIGH-A) as outcome measures. The re-
sult showed the GRID-HAMD showed higher treatment
responsiveness than SIGH-A [68].
Secondary outcomes
Secondary outcomes for treatment efficacy are severity of
anxiety assessed by SIGH-A, overall severity and improve-
ment rated by Clinical Global Impression, responder sta-
tus defined by 50 % or more baseline reduction in score
on GRID-HAMD, remission of symptom defined as less
than 8 on GRID-HAMD [77], and absence of met psychi-
atric diagnoses as assessed by SCID-IV-TR at baseline.
These secondary measures are assessed at post-treatment
(21 weeks).
SIGH-A
A semi-structured interview, SIGH-A includes 14 items
for anxiety symptoms [78, 79]. Each anxiety-related item
Table 2 Schematic diagram for the schedule of assessments
Time points (week) 0 1 2 3–4 5 6–9 10 11–14 15 16–20 21 43
Outcomes (evaluator rating)
GRID-Hamilton Rating Scale for Depression IE IE IE IE
Structural Interview Guide for Hamilton Anxiety Rating Scale IE IE IE IE
Clinical Global Impression IE IE IE IE
General Assessment of Functioning IE IE IE IE
Structural clinical interview for DSM IE IE IE
Outcomes (self-report)
Overall Anxiety Severity and Impairment Scale P P P P P P P P P P P P
Overall Depression Severity and Impairment Scale P P P P P P P P P P P P
Disorder Specific Measures P P P P
EQ-5D P P P P
Sheehan Disability Scale P P P P
Sense of Authenticity Scale P P P P
Treatment mechanism
Eysenck Personality Questionnaire Revised-Short version, Neuroticism subscale P P P P P P
Anxiety Sensitivity Inventory-III P P P P P P
Emotion Regulation Skills Questionnaire P P P P P P
Emotion Exposure Questionnaire P P P P P P
Treatment Rationale for Unified Protocol P P P P P P
Process measures
Session Rating Scale P/T P/T P/T P/T
Credibility/Expectancy Questionnaire P/T
Homework Compliance Scale T T T T T T T T
Adverse Event T T T T T/IE T T T IE IE
Neurological correlates
Functional Magnetic Resonance Imaging X X X
IE assessment of independent evaluator, P patient self-report, T therapist self-report
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is rated from 0 to 4 on the basis of frequency, degree of
distress, and symptom-related functional impairment dur-
ing the previous week. Higher scores indicate more severe
symptoms of anxiety (range: 0–56). Test–retest reliability
and interrater reliability were respectively reported as 0.89
(95 % CI 0.83–0.93) and 0.99 (95 % CI 0.98–0.99). Con-
current and construct validity were demonstrated by high
correlation with the traditional-format Hamilton Anxiety
Rating Scale (r = 0.75–0.77) and equivalent correlations
with self-report measures in the traditional format [78].
Clinical Global Impression (CGI)
CGI is an overall clinician rating of the severity of psy-
chopathology (CGI-Severity; CGI-S) and improvement
of it (CGI-Improvement, CGI-I) [80]. These are rated
from 0 to 7 based on the assessor’s overall evaluation,
which incorporates all available information about a pa-
tient’s history, psychosocial circumstances, symptoms,
behavior, and the impact of symptoms on the patient’s
ability to function [81]. In this study, essentially, the in-
dependent evaluator assesses the same patient at base-
line, mid, post, and follow-up (0, 10, 21, and 43 weeks).
Hence, the evaluator’s overall impression of longitudinal
change will be reflected in the CGI-I rating.
Global Assessment of Functioning (GAF)
The GAF is a single measure for evaluating degree of
global functioning, which is used for Axis V evaluation
in DSM-IV [82]. A score is assigned from 0–100, based
on symptom severity and the effects on social, occupa-
tional, and/or educational functioning.
Structural clinical interview for DSM-IV-TR axis I disorders
(SCID-IV-TR)
SCID-IV-TR is a semi-structured interview used to asses
the diagnostic status of DSM-IV-TR Axis I disorders
[83]. We will administer modules A (Mood Episodes), B
(Psychotic Symptoms), D (Mood Disorders), E (Substance
Use Disorders), and F (Anxiety Disorders) at baseline to
evaluate patients according to the inclusion and exclusion
criteria. At post-intervention and follow-up, the independ-
ent evaluator administers part of each module to examine
the presence or absence of the diagnoses met at baseline
assessment. The Japanese version of SCID-IV-TR has been
utilized in many clinical trials since its publication.
Overall Anxiety Severity and Impairment Scale (OASIS)
OASIS assesses the symptom of global anxiety by severity
and impairment, using a (five-point) Likert scale [84, 85].
Items cover anxiety frequency, severity, and influence on
symptoms. OASIS’s reliability and validity have been
reported among U.S. and Japanese clinical and non-
clinical populations [68, 84].
Overall Depression Severity and Impairment Scale (ODSIS)
ODSIS assesses the symptom of depression in terms of
severity and impairment [86], on a (five-point) Likert
scale. Similarly to OASIS, this scale assesses depression
frequency, severity, and related impairment. Two stud-
ies suggest its reliability and validity among U.S. and
Japanese clinical and non-clinical populations, respect-
ively [86, 87].
Disorder-specific measures
In accordance with the diagnosis by SCID-IV-TR at
baseline, each patient conducted the self-report mea-
sures to assess symptoms of met diagnoses. We used the
Beck Depression Inventory-II (BDI-II) for Depressive
Disorders [88, 89], Panic Disorder Severity Scale (PDSS)
for Panic Disorder with or without Agoraphobia [90],
Liebowitz Social Anxiety Scale (LSAS) for Social Anxiety
Disorder [91], Penn State Worry Questionnaire (PSWQ)
for Generalized Anxiety Disorder [92], Yale–Brown Ob-
sessive Compulsive Scale (Y-BOCS) for Obsessive Com-
pulsive Disorder [93], Impact of Event Scale-Revised
(IES-R) for Posttraumatic Stress Disorder [94, 95], and
Fear Questionnaire (FQ) for Agoraphobia without his-
tory of Panic Disorder [96]. All scales except for FQ have
had their reliability and validity tested.
Euro Qol (EQ-5D-3L)
Patient quality of life is assessed by Euro Qol (EQ-5D-
3L) [97, 98]. This scale consists of five items in the
domain of quality of life (mobility, self-care, usual activ-
ities, pain/discomfort, and anxiety/depression) and one
visual analogue scale regarding overall health status, ran-
ging from 0 (worst imaginable health state) to 100 (best
imaginable health state). Quality-adjusted life years will
be calculated using the Japanese EQ-5D tariff [98].
Sheehan Disability Scale (SDS)
SDS is used to assess overall functional impairment
[99, 100]. This scale consists of three domains of func-
tion (work/school, social life, and family life/home re-
sponsibilities). These items are rated on a 10-point
visual analogue scale (from “not at all” to “extremely”).
Its reliability and validity for a Japanese population has
been reported [100].
Sense of Authenticity Scale (SOA)
SOA assess one’s sense that one is being true to oneself.
It comprises seven items to be answered on a (five-
point) Likert scale (1: Strongly disagree–5: Strongly
agree). This scale was originally developed among a Jap-
anese population [101]. Research in personality, social
psychology, and positive psychology has suggested that
authenticity can be conceptualized as a healthy type of
self-esteem [101, 102] and can serve as an indicator of
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positive functioning [103]. Its reliability and validity has
been repeatedly reported among Japanese population
[101, 104].
Treatment mechanism
Neuroticism subscale of the Eysenck Personality
Questionnaire Revised–Short-Form (EPQR-S) Neur-
oticism is the tendency to experience negative affect fre-
quently and intensely, which is a putative transdiagnostic
factor for persistence of emotional disorders. This scale
assesses this personality tendency using 12 dichotomous
items. Its reliability and validity has been shown in the
U.S. and in Japanese [105, 106].
Anxiety Sensitivity Index-3 (ASI-3) ASI-3 is a self-
report questionnaire for assessing beliefs about the
feared consequences of symptoms associated with harm-
ful physical, cognitive, or social concerns [107]. The
questionnaire consists of 18 items evaluated on a four-
point Likert-type scale (0: very little; 4: very much). The
measure possesses excellent psychometric properties,
performing well on various indices of reliability and
validity [107].
Emotion Regulation Skills Questionnaire (ERSQ)
ERSQ assesses how the respondent has dealt with nega-
tive emotions in the previous week [108]. This 27-item
questionnaire has nine subscales: awareness, clarity, sensa-
tion, understanding, compassionate self-support, modifi-
cation, acceptance, tolerance, and readiness to confront.
Each subscale comprises three items, measured on a (five-
point) Likert scale (0: not at all; 4: almost always). The
scale demonstrates sufficient reliability and validity [108].
Emotion Exposure Questionnaire (EEQ) EEQ was
originally developed to assess overall patient tendency to
expose themselves to their own emotions, which is
understood to be a hallmark of the treatment mechan-
ism of the unified protocol. The items represent willing-
ness or ability to expose oneself to emotions (e.g., “Even
if it is distressing, I try to feel the emotion fully”). This
questionnaire consists of thirty items evaluated on a
(five-point) Likert-type scale.
Treatment Rationale of Unified Protocol (TRUP)
TRUP was originally developed to assess comprehension
of treatment rationale for the unified protocol. It consists
of 12 statements to be answered yes or no. We developed
two items for each treatment module (psychoeducation of
emotion, emotional awareness, cognitive reappraisal, emo-
tion avoidance and emotion-driven behavior, tolerance of
physical sensation, and emotion exposure). A sample item
regarding psychoeducation of emotion is “It is better to
suppress emotion and feelings and try not to feel it.”
Process measures
Session Rating Scale (SRS) SRS is used to assess the
therapeutic alliance [109]. It consists of four visual-
analogue items (bond, consensus of task, consensus of
goal, and overall evaluation). These item are consistent
with the conceptualization of the “working alliance” and
have good psychometric properties in terms of reliability
and validity [109].
Credibility/Expectancy Questionnaire (CEQ) CEQ as-
sesses the patient’s perception of the credibility of treat-
ment and expectancy regarding treatment. It measures
cognitive and emotional aspects of credibility and ex-
pectancy, using six items. Because there was no Japanese
version of this questionnaire, we translated it using a
rigorous back-translation procedure, with the permission
and support of the original developer of this
questionnaire.
Homework Compliance Scale (HCS) HCS is a single
measure for the therapist to assess the patient’s degree
of completion of their homework [110]. Therapists who
conduct the unified protocol assess patient homework
compliance at the end of every session, using 0–6 an-
chors. We translated this measure using a back-
translation procedure, with permission and support from
one of the original authors of the scale.
Adverse events, treatment, and assessment integrity
We defined adverse events to include any undesirable
physical or psychological event during the research
period, irrespective of its relation with the intervention.
Using the forms described above, therapists or inde-
pendent evaluators solicit patients at each visit for
assessment of occurrence or worsening of the following
symptoms: dry mouth, astriction, dysuria, accommodation
disorder, orthostatic hypotension (dizziness, lightheaded-
ness), sleepiness, malaise, insomnia, anxiety/irritation, asi-
tia, weight gain or loss, loss of sexual interest, suicidality,
suicidal attempt, and other symptoms. We assessed the
severity of the adverse event using criteria from the
Japanese version of the Common Terminology Criteria
for Adverse Events (CTCAE v4.0) [111]. This rating
system uses a (five-point) Likert-type scale (1: Grade 1,
Mild; 2: Grade 2, Moderate; 3: Grade 3, Severe or med-
ically significant but not immediately life-threatening;
4: Grade 4, Life-threatening consequences; 5: Grade 5,
Death). A “severe” adverse event is defined as one with
a 3 or higher severity rating.
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Neuropsychological assessment
Data are acquired using a 3-tesla Siemens Verio magnetic
resonance imaging (MRI) scanner (Erlangen, Germany)
with a standard Siemens 32-channel phased array head
coil. The MRI protocol includes acquisition of (1) resting-
state functional MRI (7 min), (2) T1-weighted imaging
(4 min), (3) fluid attenuated IR (FLAIR) (4 min), (4) diffu-
sion weighted imaging (DWI) (8 min), for a total of under
23 min of scanning. Resting-state fMRI will be conducted
to measure functional region connectivity, and DWI to
measure anatomical region connectivity. T1-weighted im-
ages and FRAIR images will be used for the volumetric
analysis. Participants who meet any exclusion criteria for
MRI (e.g., currently pregnant; currently breastfeeding;
wearing pacemaker, aneurysm clips, or other implants)
will be excluded from the MRI scan.
Procedure for assessment; blinding
Independent evaluators not involved with the interven-
tion for or coordination of this clinical trial will conduct
the SCID-IV-TR, GRID-HAMD, SIGH-A, and rate CGI
and GAF. These independent evaluators are prohibited
from accessing any information that could confer par-
ticipant assignment. Independent evaluators need to be
trained at least 20 h to be eligible to serve. For the pri-
mary outcome of GRID-HAMD, the evaluators trained
by attending workshops, watching a training DVD, role-
play with a mock patient, direct observation of evalu-
ation, and conducting GRID-HAMD with patients. All
evaluator assessments will be recorded and used for
other evaluator ratings to examine the reliability of the
assessment. We will choose one-fifth of the assessments
using the same random sampling technique as for treat-
ment adherence, and examine assessment integrity on
their basis.
The independent evaluators will respond to the modi-
fied version of the Independent Evaluator Knowledge of
Treatment scale at mid (10 weeks), post (21 weeks) and
follow-up assessment (43 weeks). This three-item scale
for assessing the evaluator’s knowledge of patient assign-
ment has been used in clinical trials of cognitive behav-
ior therapy for panic disorder as well as the unified
protocol for emotional disorders [112]. The independent
evaluators give their conjectures, rate their confidence in
their answer, and provide any relevant information that
led to the conjecture.
Data management and monitoring
Acquired data will be entered immediately into a data-
base constructed using Microsoft Access. Each entry
form will be restricted to the possible range of items.
Data entry and verification will be conducted independ-
ently by study assistants. Central and onsite monitoring
will be conducted periodically by a data manager at
NCNP throughout the course of the trial.
Sample size calculation
Because this clinical trial is intended to examine the effi-
cacy of a novel treatment (the unified protocol) that tar-
gets clinical populations that are heterogeneous in terms
of a traditional diagnostic perspective, we had to collect
information on the treatment effect size from various
sources in order to estimate the sample size. Estimation
was based on information from previous findings on effi-
cacy of transdiagnostic and disorder-specific CBT for
depressive and anxiety disorders, results of our pilot
study, and previous randomized controlled trials of the
unified protocol among U.S. participants [38, 68].
Meta-analysis of the RCT to examine the effect of
CBT in comparison to waiting-list on major depressive
disorder reported a standardized mean difference (SMD)
of 0.82–0.85 [113, 114]. For anxiety disorders by DSM-
IV criteria, separate meta-analysis of RCT comparing
CBT with waiting-list or seemingly equivalent condition
(e.g., no treatment, or placebo attention control) showed
an effect size of 0.82 for generalized anxiety disorder
(n = 4) [115], 0.91 for panic disorder with/without
agoraphobia (n = 7) [116], 0.93 for social anxiety dis-
order (n = 7) [117], and 1.36–1.70 for posttraumatic
stress disorder (n = 21) [118]. Finally, other meta-
analysis reported a large effect size of CBT against
waiting-list or active placebo control for emotional dis-
orders (SMD = 0.63–1.09) [119, 120].
There are few previous findings on the efficacy of the
unified protocol. In the pilot randomized controlled trial
comparing with waiting-list, an SMD of 0.52–1.11 for
depression measures and 1.10 for anxiety measures was
observed among patients with anxiety disorders [38].
Our pilot clinical trial of the unified protocol among
Japanese patients with depressive and anxiety disorders
demonstrated a within SMD of 1.70 (95 % CI = 0.81–
2.67) for GRID-HAMD, 1.14 (95 % CI = 0.40–1.89) for
ODSIS, 0.76 (95 % CI = −0.05–1.57) for BDI-II, 1.29
(95 % CI = 0.56–2.06) for SIGH-A, and 1.71 (95 % CI =
0.91–2.50) for OASIS [68].
Summarizing these findings, we assumed a large effect
size of 0.85 for UP with TAU against waiting-list with
TAU for the reduction of primary outcome assessed by
GRID-HAMD. Using G*Power, in order to detect the
difference between groups with a statistical power of
80 % for a two-tailed test, the needed sample size was
calculated to be 23 for each group. In consideration of
reported dropout rates of 11.76–15.39 % in previous
studies [38, 68], we assumed a dropout rate of 15 % and
a need to have at least 27 participants in each group to
test the primary hypothesis of this study (difference of
GRID-HAMD scores between intervention and control
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groups over the 21-week period). We will continue
recruiting patients for ancillary study of neuroimaging,
treatment process, and mechanism.
Two separate meta-analyses reported the effect size of
transdiagnostic cognitive-behavioral treatment after we
had finished designing this clinical trial and had started
the actual trial [32, 33]. These latest analyses showed the
effects of transdiagnostic treatments (including individ-
ual, group, and internet format) with control group
(waiting-list, supportive counseling, psychoeducation,
TAU, online support, or discussion forum) on the self-
report measure of anxiety (SMD = .65, 95 % CI = .34–.57,
n = 24) and depression (SMD = .80, 95 % CI = .62–.98,
n = 22). Reinholt and Krogh [33] reported pooled SMD
for four RCTs testing the efficacy of transdiagnostic in-
dividual or group treatment in comparison to waiting-
list controls as −1.00 (95 % CI −1.74–-0.26). Taking into
account this information, our estimation might have been
a bit optimistic, suggesting the risk that our method is
underpowered to test our primary hypothesis.
Statistical methods
All analyses for testing efficacy of treatment on primary
and secondary measures will be analyzed on the basis of
the intent-to-treat principle, using a linear mixed model
(LMM). The LMM approach was selected because of its
strength in dealing with missing data and its ability to
incorporate random effects (i.e., of the participants) into
the analyses. For the primary outcome, the dependent
variable is the GRID-HAMD score, and the independent
variables are assignment (i.e., intervention vs. control
group), time (i.e., 0, 10, and 21 weeks), and interaction
of the assignment and time, as a fixed-effect variable,
and participants, as random-effects variable. We will
construct a conditional growth model [121] using a
restricted maximum likelihood estimation method to
compare changes in depression severity between groups
from baseline to 21 weeks. The assessment period is
measurement time for the growth model (weeks 0, 10,
and 21), which will be coded as an ordinal scale (0, 1, 2).
We assume an unstructured error covariance for this
model. If the analysis will not converge, we will use
other covariance structures. The covariance structure
that will show convergence of the analysis and best fit to
the data, evaluated by Akaike’s information criterion, will
be used as the primary analysis.
To test robustness, we will conduct the same LMM, in-
cluding a stratified variable (depressive vs. anxiety dis-
order) as covariate and other sensitive analyses taking into
account the following aspects: ITT vs. per-protocol, and
multiple imputation methods for missing data [122].
Secondary outcomes will be analyzed in the same way as
primary outcomes. For all analyses, P < .05 will be consid-
ered statistically significant. The other statistical analyses
will be conducted to examine treatment mechanism,
process, and neurological implications in relation to
outcome.
Recruitment
This study will be announced to the psychiatrists at the
National Center of Neurology and Psychiatry (NCNP)
Hospital. When a patient requests cognitive behavioral
treatment and their primary psychiatrist deems it feas-
ible for that patient, the psychiatrist refers the patient to
the hospital’s department of clinical psychology. After
the intake session for CBT, the team in that department,
consisting of psychiatrists and clinical psychologists,
holds a conference to determine the most appropriate
CBT program for that patient. Patients with depressive
and anxiety disorders who seem suited to this study will
be referred to this clinical trial.
Discussion
Completion of this clinical trial will add to the evidence
of efficacy for transdiagnostic psychological treatment of
emotional disorders, which is not conclusive at this time
[32, 33]. This trial has importance especially with regard
to the question of the efficacy of UP for depressive disor-
ders and in an Asian population. UP is considered to be
promising as a treatment for depressive disorders be-
cause of the enormous efficacy shown in existing find-
ings for treatment of this disorder by diagnosis-specific
CBT [18, 113, 123]. There seems to be no reason to ex-
pect weaker efficacy with UP, and there is some reason
to expect enhanced efficacy of UP on depressive disor-
ders. That is, one of the core modules of UP is emotion
exposure, and the rationale of “avoiding avoidance” was
originally considered important for treatment of anxiety
disorders; however, recent advances in the understand-
ing of behavioral activation lead us to regard avoidance
as a key maintenance factor for depression. Further,
positive as well as negative emotion regulation has been
found to be an important treatment target [124]. The
UP has been modified to incorporate these findings in
order to enhance its efficacy [37].
Transdiagnostic treatments have several strengths, in-
cluding versatility to treat a broad range of emotional dis-
orders, and the relative parsimony of learning core
principles of cognitive behavioral therapy. These strengths
are especially important to clinical practice in Japan,
which has many barriers that hinder patients from receiv-
ing evidence-based treatments and where there are severe
problems for the dissemination of CBT [125]. Only three
randomized controlled clinical trials have been conducted
to assess the efficacy of CBT in medical settings in Japan
(one trial each for obsessive–compulsive disorder, insom-
nia, and hypochondria). If its efficacy is confirmed by the
present study, this versatile treatment will contribute to
Ito et al. BMC Psychiatry  (2016) 16:71 Page 11 of 15
the more rapid adoption of evidence-based treatment to
those who need it for emotional difficulties in Japan.
In addition to the results for the primary hypothesis,
secondary analyses of treatment mechanism, process,
and neurological correlates will inform better implemen-
tation of the unified protocol, and, possibly, other trans-
diagnostic treatment.
Current study status
The JUNP study began recruiting participants in December
2013. Forty-four participants have been enrolled at the
time of submission of this protocol.
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